匹伐他汀申報用全套雜質(zhì)

時間：2017/2/23閱讀：1286

匹伐他汀背景及作用機理：

冠心病是威脅人類健康和生命的常見病和多發(fā)病，以低密度脂蛋白(LDL)升高為特征的高膽固醇血癥則是誘發(fā)冠心病的主要危險因子之一。常用的降血脂藥如煙酸類、樹脂類或貝特類等療效都難盡人意，降脂作用的是被稱為他汀類(statins)的藥物。他汀類藥物共同的作用機制是都屬于3—羥—3—甲基—戊二酰輔酶A(HMG—CoA)還原酶抑制劑，目前在世界廣泛應(yīng)用的主要有6種：洛伐他汀(lovastatin)，普伐他汀(pravastatin)，辛伐他汀(simvastatin)，西立伐他汀(cerivastatin)，氟伐他汀(fluvastatin)和阿托伐他汀(atorvastatin)。而近期由Kowa公司開發(fā)的新型他汀類藥物匹他伐他汀鈣，因其良好的降膽固醇作用而被稱為“超級他汀類藥物”(Superstatin)。

深圳遠揚化學(xué)技術(shù)有限公司可提供匹伐他汀申報所用全套雜質(zhì)，隨貨附CoA證書，HNMR，MS，HPLC圖譜，純度符合申報要求，匹伐他汀雜質(zhì)為我司優(yōu)勢雜質(zhì)，長期備有庫存，發(fā)貨快。如需匹伐他汀鈣雜質(zhì)相關(guān)詳細信息，歡迎我司業(yè)務(wù)人員（何：phastandards Q.Q:781007885）獲取~

除自主品牌雜質(zhì)對照品外，我司還代理英國NIBSC標(biāo)準(zhǔn)品，美國劍橋CIL同位素標(biāo)準(zhǔn)品，美國NIST標(biāo)準(zhǔn)物質(zhì)，歐洲標(biāo)準(zhǔn)局IRMM標(biāo)準(zhǔn)物質(zhì)，加拿大TRC標(biāo)準(zhǔn)品，TLC標(biāo)準(zhǔn)品，MOLCAN標(biāo)準(zhǔn)品，NRC標(biāo)準(zhǔn)品等，歡迎洽談。

附：匹伐他汀申報用全套雜質(zhì)列表：

Pitavastatin	(+)-Monocalcium bis{(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate}
Pitavastatin Impurity 1	(3R,6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-3-hydroxy-5-oxo-6-heptenoate
Pitavastatin Impurity 2	(3S,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt
Pitavastatin Impurity 3	(4R,6S,E)-6-[2-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl] vinyl] tetrahydro-4-hydroxypyran-2-one
Pitavastatin Impurity 4	7-[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6-heptenoic Acid
Pitavastatin Impurity 5	(3R,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt
Pitavastatin Impurity 6	(3S,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt
Pitavastatin Impurity 7	(3R,5S,6E)-7-[2-Cyclopropyl-4-phenyl-quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid calcium salt
Pitavastatin Impurity 8	[[2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]methyl]triphenyl-phosphonium Bromide
Pitavastatin Impurity 9	(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-2,2-dimethyl-1,3-dioxane-6-heptenoic acid t-butyl ester
Pitavastatin Impurity 10	(3R,5S,E)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxy-N-(1-phenylethyl)hept-6-enamide
Pitavastatin Impurity 11	Sodium (5S, 6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate
Pitavastatin Impurity 12	Ethyl (3R, 6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3- quinolinyl]-3-hydroxy-5-oxo-6-heptenoate
Pitavastatin Impurity 13	Ethyl (5S, 6E)-7-[2-cyclopropyl-4-(4-flurophenyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate
Pitavastatin Impurity 14	(3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid methyl ester
Pitavastatin Impurity 15	(3R,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester
Pitavastatin Impurity 16	(3R,5S)-5-(6-Cyclopropyl-10-fluoro-7,8-dihydrobenzo[k]phenanthridin-8-yl)-3,5-dihydroxypentanoic acid sodium salt
Pitavastatin Impurity 17	2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinemethanol
Pitavastatin Impurity 18	(3R,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester
Pitavastatin Impurity 19	(3S,5R,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester
Pitavastatin Impurity 20	(3S,5S,6E)-7-[2-Cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid ethyl ester
Pitavastatin Impurity 21	(3R,5S,6E)-7-(2-Cyclopropyl-4-phenyl-3-quinolinyl)-3,5-dihydroxy-6-heptenoic Acid tert-Butyl Ester
Pitavastatin Impurity 22	2-((4R,6S)-6-((E)-2-(2-Cyclopropyl-4-phenylquinolin-3-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetic Acid tert-Butyl Ester

匹伐他汀申報用全套雜質(zhì)

會員登錄

收藏該商鋪

提示